Mass. Movers

Cambridge’s Idenix up on pipeline update


Cambridge’s Idenix Pharmaceuticals Inc. reported third-quarter revenue of less than $0.1 million, compared to $32.3 million a year ago. The company said it lost $34 million, compared to a profit of $4.3 million, last year. But investors showed optimism after Idenix gave an update on its product pipeline. It said that its hepatitis C treatment has received approval to enter clinical trials in Canada and Belgium, and that all patients had completed enrollment in the first phase of its midstage trial involving samatasvir, its NS5A inhibitor.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of